Clinical Trial Update: Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a personalized active immunotherapy vaccine and sargramostim after standard Rituximab and chemotherapy for initial treatment of Non-Hod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Personalized Active Immunotherapy (Vaccine Therapy)
• sargramostim (sargramostim)

Snippet

Sponsor: Genitope Corporation | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED